Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma

被引：25
|
作者：
Rasi, G [1 ]
Terzoli, E
Izzo, F
Pierimarchi, P
Ranuzzi, M
Sinibaldi-Vallebona, P
Tuthill, C
Garaci, E
机构：
[1] CNR, Ist Med Sperimentale, I-00137 Rome, Italy
[2] Univ Rome Tor Vergata, Rome, Italy
[3] Ist Regina Elena, I-00161 Rome, Italy
[4] SciClone Pharmaceut Inc, San Mateo, CA USA
来源：
MELANOMA RESEARCH | 2000年 / 10卷 / 02期
关键词：
advanced melanoma; combination treatment; DTIC; interferon; thymosin-alpha; 1;
D O I：
10.1097/00008390-200010020-00012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：189 / 192
页数：4
相关论文
共 50 条
  • [1] Combined treatment with pegylated interferon-α-2a and dacarbazine in patients with advanced metastatic melanoma
    Hauschild, Axel
    Dummer, Reinhard
    Ugurel, Selma
    Kaehler, Katharina C.
    Egberts, Friederike
    Fink, Wolfram
    Both-Skalsky, Jeannine
    Laetsch, Barbara
    Schadendorf, Dirk
    CANCER, 2008, 113 (06) : 1404 - 1411
  • [2] Effects of interferon-α, verpamil and dacarbazine in the treatment of advanced malignat melanoma
    Andersson, R
    Hofer, PA
    Riklund-Åhlström, K
    Henriksson, R
    MELANOMA RESEARCH, 2003, 13 (01) : 87 - 91
  • [3] THE COMBINED DACARBAZINE-INTERFERON-ALPHA-2A-TREATMENT IN ADVANCED MALIGNANT-MELANOMA
    GUDAT, W
    SCHRAMM, P
    WALTER, C
    KNOP, J
    TUMORDIAGNOSTIK & THERAPIE, 1992, 13 (04) : 162 - 165
  • [4] Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-α
    Konjevic, G
    Jovic, V
    Radulovic, S
    Jelic, S
    Dzodic, R
    Spuzic, I
    NEOPLASMA, 2001, 48 (03) : 175 - 181
  • [5] Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-α in patients with advanced melanoma
    Vuoristo, MS
    Hahka-Kemppinen, M
    Parvinen, LM
    Pyrhönen, S
    Seppä, H
    Korpela, M
    Kellokumpu-Lehtinen, P
    MELANOMA RESEARCH, 2005, 15 (04) : 291 - 296
  • [6] Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
    Daponte, Antonio
    Signoriello, Simona
    Maiorino, Luigi
    Massidda, Bruno
    Simeone, Ester
    Grimaldi, Antonio Maria
    Caraco, Corrado
    Palmieri, Giuseppe
    Cossu, Antonio
    Botti, Gerardo
    Petrillo, Antonella
    Lastoria, Secondo
    Cavalcanti, Ernesta
    Aprea, Pasquale
    Mozzillo, Nicola
    Gallo, Ciro
    Comella, Giuseppe
    Ascierto, Paolo Antonio
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [7] Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
    Antonio Daponte
    Simona Signoriello
    Luigi Maiorino
    Bruno Massidda
    Ester Simeone
    Antonio Maria Grimaldi
    Corrado Caracò
    Giuseppe Palmieri
    Antonio Cossu
    Gerardo Botti
    Antonella Petrillo
    Secondo Lastoria
    Ernesta Cavalcanti
    Pasquale Aprea
    Nicola Mozzillo
    Ciro Gallo
    Giuseppe Comella
    Paolo Antonio Ascierto
    Journal of Translational Medicine, 11
  • [8] Combined treatment with dacarbazine, cisplatin and interferon a in metastatic melanoma.
    Tessier, MH
    Mansat, E
    Legoux, B
    Litoux, P
    Dreno, B
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1996, 123 (09): : 538 - 542
  • [9] Interferon-α combined with radiotherapy in the treatment of unresectable melanoma
    Nguyen, NP
    Sallah, S
    Childress, C
    Salehpour, MR
    Karlsson, U
    CANCER INVESTIGATION, 2001, 19 (03) : 261 - 265
  • [10] A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma
    Vihinen, Pia P.
    Hernberg, Micaela
    Vuoristo, Meri-Sisko
    Tyynela, Kristiina
    Laukka, Marjut
    Lundin, Johan
    Ivaska, Johanna
    Pyrhonen, Seppo
    MELANOMA RESEARCH, 2010, 20 (04) : 318 - 325
12345